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Abstract Both cisplatin and the estrogen receptor (ER) are
known to bend DNA. The influence of the bending of sequences
by the d(GpG)cisPt adduct binding of ER to estrogen response
element (ERE)-like sequences was examined. Three ERE-like
oligonucleotides with different affinities for ER and which
include a GG in the linker sequence were designed in order to
form a single central d(GpG)cisPt adduct. Using electrophoretic
mobility shift assay and Scatchard analysis, it was shown that the
presence of a single d(GpG)cisPt adduct in the linker sequence
decreases the ER affinity for DNA. These results do not support
a critical role of a DNA bend in the initial recognition of ERE by
ER. Then, the platination of DNA outside of the ERE half-sites
decreases the interaction of ER with ERE.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
cis-Diamminedichloroplatinum(II) (cisplatin or CDDP) is a
chemotherapeutic agent widely used in the treatment of sev-
eral types of human cancer [1] ; its cytotoxicity is believed to
be mediated by cisplatin-DNA adducts [2]. The in vitro as
well as in vivo major adducts formed by CDDP are the N7,
N7 d(GpG)cisPt (w65% of the platinum bound) and d(ApG)-
cisPt (w25%) [3]. They alter the DNA structure [4], block
replication and transcription [2,5] and activate a programmed
cell death [6].
The d(GpG)cisPt and d(ApG)cisPt adducts bend DNA to-
wards the major groove by 35^55‡ [7] and unwind it by 13‡
[8]. Recently, a number of cellular proteins have been de-
scribed that interact preferentially with cisplatin-damaged
DNA sites [9]. Cisplatin induces a DNA distortion which is
recognized by high mobility group proteins (HMG) such as
HMG1 [10] and HMG2 [11], human upstream binding factor
(hUBF) [12], mitochondrial transcription factor [13], SSRP1
[14], testis HMG protein (tsHMG) [15] or sex determining
region Y protein [16]. Proteins without an HMG domain mo-
tif, such as TBP, are also able to bind to the 1,2-intrastrand
CDDP adducts [17]. It was not known whether the binding of
other classes of nuclear proteins, in particular nuclear recep-
tors, could be modi¢ed by cisplatin adducts.
The estrogen receptor (ER) is a member of a superfamily of
nuclear receptors that have common structural and functional
domains with two highly conserved regions: the central DNA
binding domain and the C-terminal hormone binding domain
[18]. The most highly conserved region among the members of
this superfamily of receptors is the DNA binding domain.
This region is responsible for the speci¢c interaction of ER
with an estrogen response element (ERE), a palindrome con-
sisting of GGTCA half-sites separated by a linker sequence of
3 bp [19]. Nardulli et al. demonstrated that ER binding in-
duces a 54‡ bending of the ERE-containing DNA fragments
[20]. Following a hormonal stimulation, the ER binds to an
ERE as a homodimer, leading to changes in transcription of
hormone responsive genes; it could be implicated in the de-
velopment of hormonally dependent cancers [21].
Since CDDP and ER are known to bend DNA to a similar
extent, we assessed if DNA bending has a critical role in the
recognition of ERE by ER. Therefore, we examine the
changes in binding of ER to ERE modi¢ed by the major
cisplatin d(GpG)cisPt adduct in the linker sequence in order
to induce a bend of the oligonucleotide able to mimic that of
ERE upon ER binding. We selected oligonucleotides of high,
intermediate and low ER a⁄nities, all containing a single GG
in the linker sequence. None of them contained a GG or an
AG susceptible to give cisplatin adducts in the modi¢ed ERE
half-sites. We show here that the presence of a single
d(GpG)cisPt adduct in the linker sequence decreases the ER
a⁄nity for DNA. Moreover, the platination of DNA sequen-
ces which are not ER binding sites, does not induce their
recognition by this protein. These results do not support a
critical role of a DNA bend in the initial recognition of
ERE by ER.
2. Materials and methods
2.1. Expression of ER and its deleted fragments
Expression vectors for human ER were previously described by
Green and Chambon, and Ylicomi et al. [22,23]. The cell extracts
were prepared in COS-7 cells transfected with ER as described by
Massaad et al. [24].
2.2. Oligonucleotides and platination
Five ERE-like oligonucleotides of 20 bp containing modi¢ed ERE
half-sites were synthesized. Table 1 represents the sequences studied.
ERE(1) is a classical ERE consensus sequence which consist of two
half-sites separated by 3 bp (TGG). ERE(2) di¡ers from the consensus
sequence by 1 bp (substitution of the second G in the ¢rst half-site by
T). ERE(3) di¡ers from the consensus sequence by 2 bp (substitution
of GG in the ¢rst half-site by TA). ERE(4) di¡ers from the consensus
sequence by 4 bp (substitution in the ¢rst and second half-site of both
G and both C by TA).
The purity of the three ERE-like sequences (ERE(2), ERE(3) and
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ERE(4)) which do not contain a GG in the half-sites was checked by
high performance liquid chromatography and then allowed to react
with the diaqua form of cisplatin as previously described by Reeder et
al. [25]. After the single-stranded oligonucleotides platination, adducts
were identi¢ed by enzymatic reactions of the products followed by
MALDI mass spectroscopy analysis of the isolated fragments [26].
2.3. Preparation of competitors and radiolabelled probes
A 20 bp oligonucleotide containing a single, centrally located
d(GpG)cisPt adduct and its analogous unmodi¢ed fragments were
used as both competitor DNAs and probes in electrophoretic mobility
shift assay (EMSA). For EMSA and Scatchard studies, a high speci¢c
activity was required, the non-coding strand was 3P-end-labelled by
using the Klenow fragment of DNA polymerase I in the presence of
[K-32P]dCTP (s 3000 Ci/mmol; 1 Ci = 37 GBq).
2.4. EMSA
The ability of the various platinated or untreated EREs to compete
with radiolabelled consensus was investigated by competitive EMSA
as previously described [24] using the recombinant ER-K (3.5 pmol)
protein (Panvera Corporation, Madison, WI, USA). Free and bound
forms of ERE were quanti¢ed by a phosphorimager (Image Quant
Software). The ratio of the radioactivity included in the band over
total radioactivity was calculated and results were expressed as per-
cent of control.
The a⁄nity of the ER to the platinated or unplatinated ERE was
evaluated using Scatchard assays. 20 Wl of ER-containing COS-7 ex-
tract was incubated with 2Ureaction mix and an increasing amount of
either labelled ERE(2) or [ERE(2)-Pt]. Free and bound forms were
excised from the gel and counted in a scintillation counter. Scatchard
plots were analyzed by graphpad inplot for estimation of the dissoci-
ation constant (Kd).
3. Results
3.1. Analysis of ER interaction with ERE-like sequences
We evaluated the ability of ER to interact with the ERE
sequences listed in Table 1. We performed competitive EMSA
assessing the binding of recombinant ER to a radiolabelled
ERE(1) in the absence or presence of increasing amounts of
unlabelled ERE(1), ERE(2), ERE(3) and ERE(4). In this as-
say, the binding of ER to an unlabelled ERE-like sequence
resulted a decrease in the amounts of bound probe. As can be
seen in Fig. 1A, ERE(2) and ERE(3) were able to compete for
ER binding, whereas ERE(4) was not. After quanti¢cation,
the relative a⁄nities of the EREs to ER were as follows:
ERE(1)vERE(2)sERE(3) (10-fold)DERE(4) (Fig. 1B).
3.2. A⁄nity of ER to cisplatin-modi¢ed sequences
ERE(1) was not a good candidate for platination because of
the presence of a GG in the ¢rst half-site which would give an
additional cisplatin adduct. For that reason, only ERE(2),
ERE(3) and ERE(4) were platinated. The e¡ect of platination
on the ability of ERE(2), ERE(3) and ERE(4) to compete
with radiolabelled consensus ERE for ER binding was exam-
ined. Recombinant ER was incubated with a radiolabelled
Table 1
Nucleotide sequences of EREs
Element Sequencea
Consensus 5P-GGTCA NNN TGACC-3P (strand I)
3P-CCAGT NNN ACTGG-5P (strand II)
ERE(1) 5P-GAAAGGTCA TGG TGACCTAC-3P (strand I)
3P-CTTTCCAGT ACC ACTGGATG-5P (strand II)
ERE(2) 5P-GAAATGTCA TGG TGACCTAC-3P (strand I)
3P-CTTTACAGT ACC ACTGGATG-5P (strand II)
ERE(3) 5P-GAAATATCA TGG TGACCTAC-3P (strand I)
3P-CTTTATAGT ACC ACTGGATG-5P (strand II)
ERE(4) 5P-GAAATATCA TGG TGATATAC-3P (strand I)
3P-CTTTTAAGT ACC ACTATATG-5P (strand II)
aUnderlined bases are those that di¡er from consensus sequence, in
bold the linker sequence.
Fig. 1. Assessment of ER a⁄nity for the ERE-like sequences. A: The binding of human recombinant ER (Panvera) to a radiolabelled double-
stranded consensus ERE(1) (0.1 ng) was competed by increasing amounts of unlabelled double-stranded ERE(1) (lanes 2^5), ERE(2) (lanes 6^
9), ERE(3) (lanes 10^13) and ERE(4) (lanes 14^17) (10-, 30-, 100- and 300-fold excess). No competitors were added in lane 1. B: The ratio of
the radioactivity included in the band over total radioactivity was calculated and the results were expressed as percent of control. Each point
represents the mean þ S.D. of four independent experiments.
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ERE(1) and with increasing amounts of unmodi¢ed or cispla-
tin-treated oligonucleotides ERE(2), ERE(3) and ERE(4).
3.2.1. A d(GpG) cisplatin adduct decreases ER binding to
ERE(2). ERE(2) was treated with cis[Pt(H2O)2(NH3)2]2,
leading to a single centrally located 1,2-intrastrand d(GpG)
chelate of the cis[Pt(NH3)2]2 moiety in the oligonucleotide
[ERE(2)-Pt]. We used the ERE(1) sequence as a probe at
0.1 ng and as competitors either ERE(2) or [ERE(2)-Pt] at
an excess of 10-, 30-, 100-, 300- and 1000-fold. As seen in
Fig. 2, ERE(2) was about 4-fold more e⁄cient than
ERE(2)-Pt for ER binding.
In order to determine whether the cisplatin adduct modi¢ed
the a⁄nity of the receptor for the ERE(2) oligonucleotide, we
performed Scatchard assays using ER prepared in COS-7 cells
incubated with increasing amounts of either labelled ERE(2)
or [ERE(2)-Pt]. Fig. 3A^C shows of such an experiment the
corresponding Scatchard plot. For each oligonucleotide con-
centration, the amount of ER-ERE(2) complex was more
Fig. 2. Assessment of ER a⁄nity for the ERE(2) and platinated ERE(2) sequences. A: EMSA was performed with puri¢ed human recombinant
ER (Panvera) and the ERE(1) probe (0.1 ng) in the absence (lanes 1 and 7) or the presence of increasing amounts of unlabelled competitors
(10-, 30-, 100-, 300- and 1000-fold excess) ERE(2) (lanes 2^6) or [ERE(2)-Pt] (lanes 8^12). B: The ratio of the radioactivity included in the
band over total radioactivity was calculated and the results were expressed as percent of control. Each point represents the mean þ S.D. of three
independent experiments.
Fig. 3. Determination of the dissociation constant (Kd) of ERE(2) and [ERE(2)-Pt] by Scatchard analysis. A and B: EMSA was performed us-
ing HER overexpressed in COS-7 cells and increasing amounts of radiolabelled ERE(2) (A) or [ERE(2)-Pt] (B) (0.025U106 cpm to 2.5U106
cpm). C: Complexes and free probes were cut o¡ the gel and counted. The ¢gure shows a representative experiment that was repeated four
times.
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abundant than that of the complex ER-[ERE(2)-Pt]. After
quanti¢cation, Scatchard analysis revealed that the dissocia-
tion constant (Kd) value was 4-fold lower for ERE(2)
(Kd = 0.93 nM) than for [ERE(2)-Pt] (Kd = 3.77 nM) (Fig.
3C) while the number of total sites was similar. This result
indicates a decreased a⁄nity of ER for [ERE(2)-Pt].
3.2.2. A d(GpG) cisplatin adduct abolishes ER binding to
ERE(3) and does not a¡ect the ER binding to ERE(4). The
ability of unmodi¢ed or platinated ERE(3) to compete with
radiolabelled ERE(1) for binding to the ER protein. We per-
formed an EMSA using as probe the ERE(1) sequence at 0.1
ng and as competitors ERE(3) or [ERE(3)-Pt] at 1, 3, 10, 30
100 ng. As seen in Fig. 4, ERE(3) competes approximately 10-
fold better than [ERE(3)-Pt] for ER binding, suggesting that
the a⁄nity of ER for [ERE(3)-Pt] is very low. This was con-
¢rmed by saturation studies showing that while a complex
was formed between ER and ERE(3), no association was
detected between ER and [ERE(3)-Pt] even at high concen-
tration of the probe (data not shown). In the case of ERE(4),
no binding was observed with either the platinated or unpla-
tinated oligonucleotide, thus the structural modi¢cation eli-
cited by the cisplatin adduct does not increase the ER a⁄nity
to this oligonucleotide.
4. Discussion
We analyzed the e¡ect of cisplatin adduct on the binding of
ER to various modi¢ed EREs. The rationale supporting this
work was the observation that both cisplatin adducts and ER
binding trigger a similar bending of DNA at least in some
studies. We therefore used three di¡erent oligonucleotides,
ERE(2), ERE(3) and ERE(4), displaying a high, medium
and very low activity for the ER. All these sequences con-
tained a single GG in the linker sequence and were platinated
on this GG in order to induce a bend of the oligonucleotide
able to mimic that of ERE upon ER binding. None of the
sequences studied contained a GG or an AG susceptible to
give cisplatin adducts in the modi¢ed ERE half-sites.
Following GG platination, the a⁄nity of ER for all the
modi¢ed sequences either decreased or was completely abol-
ished. In the case of ERE(3), the a⁄nity of ER for the plati-
nated sequence is decreased about 4-fold. ER binding to
[ERE(4)-Pt] is completely abolished and that to [ERE(3)-Pt]
remains very weak at best. The data show that the DNA
modi¢cations induced by the d(GpG)cisPt adduct do not fa-
vor the binding of ER despite the similar bends induced by
the platinum chelate and for an ER bound DNA. Further-
more, although unlikely, we cannot exclude that decreased
a⁄nity of ER for platinated sequences could re£ect a steric
hindrance caused by the d(GpG)cisPt adduct which could in-
hibit the ability of the two ER monomers to maintain contact
and form a stable ER dimer.
The d(GpG)cisPt adduct leads to both DNA bending to-
wards the major groove and unwinding of the double helix
together with an extension of the minor groove. Several bio-
chemical and biophysical studies have assessed the structural
changes caused by cisplatin adducts [27^30]. Electrophoretic
mobility studies gave a 32^34‡ range for bending [27], whereas
NMR associated to molecular modeling gave a 58^78‡ range
for bending and 13^25‡ unwinding [28,29]. For the same plati-
nated oligonucleotide, analyzed by the same group, di¡erent
values were found by X-ray di¡raction [30] and solution
NMR investigations [28]. These structural di¡erences could
depend on the stacking of the oligonucleotide in the crystal
structure.
In the case of the ER, the structural and biochemical stud-
ies have revealed that ER DBD interacts with the major
groove of the DNA helix and occupies both half-sites of the
palindromic ERE sequence [31^33]. ERE is bent toward the
major groove by about 54‡ when ER is bound [34^36]. No
unwinding has been reported. It was suggested that the struc-
tural modi¢cation of DNA by ER is a consequence of ER
binding, and that such a structure could be a critical feature
of the e⁄ciency of ER binding [37]. The decrease or absence
of ER binding to GG-cisPt-containing ERE-like sequences
may be due to a con¢guration or £exibility of the platinum
Fig. 4. Assessment of ER a⁄nity for the ERE(3) and platinated ERE(3) sequences. A: EMSA was performed with puri¢ed human recombinant
ER (Panvera) and the ERE(1) probe (0.1 ng) in the absence (lanes 1 and 7) or the presence of increasing amounts of unlabelled competitors
(10-, 30-, 100-, 300- and 1000-fold excess) ERE(3) (lanes 2^6) or [ERE(3)-Pt] (lanes 8^12). B: The ratio of the radioactivity included in the
band over total radioactivity was calculated and the results were expressed as percent of control. Each point represents the mean þ S.D. of three
independent experiments.
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adduct inappropriate for e⁄cient ER recognition. This obser-
vation can be related to the results of Kim et al., which dem-
onstrated that prebending of the ERE toward the minor
groove reduced the binding of ER DNA to its speci¢c site
[38]. They concluded that the interaction of a eukaryotic tran-
scription factor with its recognition sequence can be strongly
in£uenced by altering the topology through prebending of the
DNA. Thus, while the direction of DNA bending by cisplatin
is similar to that induced by ER, other structural modi¢ca-
tions are probably di¡erent.
Several authors reported that the cisplatin-DNA adducts
cause structural distortions in DNA that mimic the conforma-
tion of the preferred natural binding sites of some nuclear
proteins luring them away from their natural binding sites
and decreasing their biological e¡ects. The proteins described
could be classi¢ed into two groups, the repair proteins and the
architectural proteins. The repair proteins, such as xeroderma
pigmentosum group A and E, UV-damage recognition pro-
tein, T4 endonuclease VII [39^44], recognize cisplatin adducts
and are involved in damage recognition as a ¢rst step of the
repair pathways. The architectural proteins, such as HMG1/2,
hUBF, SSRP1 or tsHMG, are generally abundant nuclear or
chromatin proteins that have an architectural role in the for-
mation of functional higher order protein/DNA or protein/
protein complexes (for review, see [45]). Since the binding of
those proteins to DNA induces a deformation of DNA struc-
ture which is important for proper promoter architecture, the
structural distortions caused by cisplatin adducts may create a
key geometric feature that favors the binding of these pro-
teins. In contrast with those proteins, the ER DBD binds in
the major groove of the DNA, giving sequence-speci¢c H-
bonds with bases comprising part of the ERE palindrome,
and forming extensive contacts with the phosphate backbone
[32,33]. In this complex, the DNA is bent [20] toward the
major groove [36].
In conclusion, this study demonstrates that the d(GpG)cisPt
adduct decreases or abolishes ER ability to interact with
ERE-like sequences and does not increase the a⁄nity of the
ER for DNA sequences that are not normally speci¢c binding
sites for it. The most likely hypothesis is that the conforma-
tion or £exibility of the cisplatin adduct is inappropriate for
ER recognition.
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